The FDA has approved sublingual Zubsolv (buprenorphine/naloxone), from Orexo, as maintenance treatment for people suffering from Opioid Dependence. Studies indicate...
Orexo has announced it has submitted an application to the FDA for an expanded label of Zubsolv (buprenorphine/naloxone CIII sublingual...
Orexo files at FDA for Zubsolv (buprenorphine and naloxone) for the treatment of Opioid Dependence. The earlier submission is expected...
Orexo has announced the results of two clinical trials assessing Zubsolv (buprenorphine and naloxone) for induction of buprenorphine maintenance therapy...
The FDA has approved an extension of the indication of Zubsolv (buprenorphine/naloxone CIII sublingual tablet), from Orexo, for induction of...
Mundipharma and Orexo AB have announced the submission of a regulatory submission of a Marketing Authorisation Application (MAA) for Zubsolv...
Orexo AB (publ.) announced that the European Medicines Agency (EMA) has granted a Marketing Authorization (MA) for Zubsolv (buprenorphine and...
Mundipharma and Orexo AB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Orexo announced data from a 24-week clinical trial assessing the long-term safety and efficacy of Zubsolv (buprenorphine/naloxone) sublingual tablet (CIII)...